COMMUNIQUÉS West-GlobeNewswire

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device

02/09/2024 - 22:05

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval on track for the end [...]

Nyxoah Sonne la Cloche de Clôture sur le Nasdaq alors qu'elle se Prépare à Lancer sa Technologie Innovante pour l'Apnée du Sommeil sur le Marché Américain

02/09/2024 - 22:05

Nyxoah Sonne la Cloche de Clôture sur le Nasdaq alors qu'elle se Prépare à Lancer sa Technologie Innovante pour l'Apnée du Sommeil sur le Marché Américain L'entreprise a complété la demande d'enregistrement [...]

Trading by management and close relations of management

02/09/2024 - 18:36

Please read the full announcement in PDF Attachment 2024_31_Trading_By_Management

Trading by management and close relations of management

02/09/2024 - 18:27

Please read the full announcement in PDF Attachment 2024_30_Trading_By_Management

Amended terms of Idorsia’s 2024 convertible bonds become effective

02/09/2024 - 17:45

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal was filed – the [...]

Claritas NucMed Technologies Secures Approval for its Subsidiary Claritas NucMed Tech Brazil to Forge Ahead the Commercialization of its Cutting-Edge Nuclear Medicine Software Solutions in Brazil

02/09/2024 - 16:00

LONDON and SAO PAULO, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (“Claritas NucMed”), a company specializing in image processing, lesion detection and quantification for the nuclear medicine [...]

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

02/09/2024 - 13:45

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action —Largest randomized data set to date on bioadaptor, with [...]

Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action unique

02/09/2024 - 13:45

Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action unique — Le pool [...]

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/09/2024 - 13:30

CLEVELAND, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

02/09/2024 - 13:00

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innovation-led cell and [...]

GUERBET : Bilan semestriel du contrat de liquidité

02/09/2024 - 12:59

Bilan semestriel du contrat de liquidité Villepinte, le 2 septembre 2024 Au titre du contrat de liquidité confié par la société GUERBET à Exane BNP Paribas, en date de dénouement du 30 juin 2024, les moyens suivants [...]

Trading in GN Store Nord shares by board members, executives and associated persons

02/09/2024 - 12:39

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]

Myocene Helps the French Handball Team

02/09/2024 - 09:00

LIÈGE, Belgium, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Myocene, the Belgian sportstech company which is developing a device for the objective measurement of muscular fatigue for top-level sportsmen and women, today [...]

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

02/09/2024 - 09:00

The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic and [...]

Myocene Helps the French Handball Team

02/09/2024 - 09:00

LIÈGE, Belgium, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Myocene, the Belgian sportstech company which is developing a device for the objective measurement of muscular fatigue for top-level sportsmen and women, today [...]

MYOCENE AU SERVICE DE L'ÉQUIPE DE FRANCE DE HANDBALL

02/09/2024 - 09:00

LIÈGE, Belgique, 02 sept. 2024 (GLOBE NEWSWIRE) -- Myocene, la sportstech liégeoise qui développe un dispositif de mesure objective de la fatigue musculaire à destination des sportifs de haut niveau, annonce aujourd’hui [...]

PCI Biotech: Employee share option scheme

02/09/2024 - 07:53

Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual General Meeting 24 May [...]

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

02/09/2024 - 07:00

Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, [...]

CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des personnes avec une sclérose en plaques...

02/09/2024 - 07:00

Le tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament ayant permis d’observer une réduction de l’accumulation du handicap chez des personnes présentant [...]